ArticleJTO clinical and research reports2026
Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study.
Akito Miyazaki et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.